MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561748 | Name: YQA14

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YQA14 is a selective D3 receptor antagonist.

Chemical Structure

YQA14
YQA14
CAS#1221408-42-9

Theoretical Analysis

MedKoo Cat#: 561748

Name: YQA14

CAS#: 1221408-42-9

Chemical Formula: C23H27ClN4O3

Exact Mass: 442.1772

Molecular Weight: 442.94

Elemental Analysis: C, 62.37; H, 6.14; Cl, 8.00; N, 12.65; O, 10.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
YQA14; YQA-14; YQA 14;
IUPAC/Chemical Name
N-[4-[4-(5-Chloro-2-methylphenyl)-1-piperazinyl]butyl]-2,3-dihydro-2-oxo-5-benzoxazolecarboxamide
InChi Key
VIZDBZXBKIEXRK-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H27ClN4O3/c1-16-4-6-18(24)15-20(16)28-12-10-27(11-13-28)9-3-2-8-25-22(29)17-5-7-21-19(14-17)26-23(30)31-21/h4-7,14-15H,2-3,8-13H2,1H3,(H,25,29)(H,26,30)
SMILES Code
O=C(C1=CC=C(OC(N2)=O)C2=C1)NCCCCN3CCN(C4=CC(Cl)=CC=C4C)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 442.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sun L, Song R, Chen Y, Yang RF, Wu N, Su RB, Li J. A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice. Acta Pharmacol Sin. 2016 Feb;37(2):157-65. doi: 10.1038/aps.2015.96. Epub 2015 Dec 21. PubMed PMID: 26687935; PubMed Central PMCID: PMC4753378. 2: Liu F, Wang X, Li Z, Li J, Zhuang X, Zhang Z. P-Glycoprotein (ABCB1) limits the brain distribution of YQA-14, a novel dopamine D3 receptor antagonist. Chem Pharm Bull (Tokyo). 2015;63(7):512-8. doi: 10.1248/cpb.c15-00089. PubMed PMID: 26133067. 3: Chen Y, Song R, Yang RF, Wu N, Li J. A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats. Eur J Pharmacol. 2014 Nov 15;743:126-32. doi: 10.1016/j.ejphar.2014.09.026. Epub 2014 Sep 26. PubMed PMID: 25261038. 4: Liu F, Zhuang X, Yang C, Li Z, Xiong S, Zhang Z, Li J, Lu C, Zhang Z. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. Biopharm Drug Dispos. 2014 Jul;35(5):296-307. doi: 10.1002/bdd.1897. Epub 2014 Apr 13. PubMed PMID: 24647883. 5: Hu R, Song R, Yang R, Su R, Li J. The dopamine D(3) receptor antagonist YQA14 that inhibits the expression and drug-primed reactivation of morphine-induced conditioned place preference in rats. Eur J Pharmacol. 2013 Oct 24. pii: S0014-2999(13)00782-6. doi: 10.1016/j.ejphar.2013.10.026. [Epub ahead of print] PubMed PMID: 24513519. 6: Hu R, Song R, Yang R, Su R, Li J. The dopamine D(3) receptor antagonist YQA14 that inhibits the expression and drug-prime reactivation of morphine-induced conditioned place preference in rats. Eur J Pharmacol. 2013 Nov 15;720(1-3):212-7. PubMed PMID: 24436985. 7: Song R, Bi GH, Zhang HY, Yang RF, Gardner EL, Li J, Xi ZX. Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats. Neuropharmacology. 2014 Feb;77:398-405. doi: 10.1016/j.neuropharm.2013.10.010. Epub 2013 Oct 28. PubMed PMID: 24176392; PubMed Central PMCID: PMC3867233. 8: Song R, Zhang HY, Peng XQ, Su RB, Yang RF, Li J, Xi ZX, Gardner EL. Dopamine D(3) receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice. Neuropharmacology. 2013 Sep;72:82-7. doi: 10.1016/j.neuropharm.2013.04.042. Epub 2013 May 2. PubMed PMID: 23643749; PubMed Central PMCID: PMC3742042. 9: Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, Li X, Gaál J, Xi ZX, Gardner EL. YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol. 2012 Mar;17(2):259-73. doi: 10.1111/j.1369-1600.2011.00317.x. Epub 2011 Apr 20. PubMed PMID: 21507153; PubMed Central PMCID: PMC5531447.

View History

YM116

YM116